Brian T Hill
Overview
Explore the profile of Brian T Hill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
6491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Arustamyan M, Kibrik P, Hatipoglu D, Bungo B, Mentias A, Hill B, et al.
Eur J Haematol
. 2022 Aug;
109(6):696-710.
PMID: 36030394
B-cell malignancies, most notably lymphomas, make up most of the non-Hodgkin lymphomas in the United States. There are limited randomized data comparing first- and second-generation Bruton tyrosine kinase (BTK) inhibitors....
32.
Jacobs M, Jain M, Gao F, Nastoupil L, Spiegel J, Lin Y, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jul;
22(10):753-759.
PMID: 35780055
Background: The majority of patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, develop cytokine release syndrome (CRS). Whether the lack...
33.
Mian A, Bhattarai N, Sheu M, Ondrejka S, Caimi P, Hill B
Br J Haematol
. 2022 Jun;
198(5):e71-e74.
PMID: 35733291
No abstract available.
34.
Gaffney K, Urban T, Lucena M, Anwer F, Dean R, Gerds A, et al.
J Oncol Pharm Pract
. 2022 Jun;
:10781552221104422.
PMID: 35673764
Busulfan-based conditioning regimens are associated with serious toxicities and literature reports increased risk of toxicities when daily area under the curve concentrations exceed 6000 µM-minute. We implemented real time pharmacokinetic-guided...
35.
Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B, et al.
J Clin Oncol
. 2022 Jun;
41(3):555-567.
PMID: 35658525
Purpose: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the...
36.
Jacobson C, Locke F, Ma L, Asubonteng J, Hu Z, Siddiqi T, et al.
Transplant Cell Ther
. 2022 May;
28(9):581.e1-581.e8.
PMID: 35609867
Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory (r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients receiving axi-cel...
37.
Hegde P, Rybicki L, Serafino S, Bernhard L, Corrigan D, Anwer F, et al.
Bone Marrow Transplant
. 2022 Apr;
57(6):1031-1033.
PMID: 35428866
No abstract available.
38.
Baidoun F, Alhaj Moustafa M, Tun H, Hill B
Clin Lymphoma Myeloma Leuk
. 2022 Feb;
22(7):e485-e494.
PMID: 35110006
Introduction: Primary effusion lymphoma (PEL) is a rare HHV8(+) non-Hodgkin lymphoma associated with HIV infection or other causes of immunosuppression. Large-scale studies describing the natural history of this entity are...
39.
Hu R, Wei W, Mian A, Gonter-Aubin K, Kabel C, Mato A, et al.
Eur J Haematol
. 2022 Jan;
108(5):379-382.
PMID: 35043475
Introduction: Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations. At...
40.
Kapoor I, Bodo J, Hill B, Almasan A
Cell Death Dis
. 2021 Nov;
12(11):1061.
PMID: 34750354
Aberrant microRNA (miR) expression plays an important role in pathogenesis of different types of cancers, including B-cell lymphoid malignancies and in the development of chemo-sensitivity or -resistance in chronic lymphocytic...